Form 4: BioLargo Director Linda Park Granted Stock Options

BioLargo director Linda Park received 110,294 stock options as compensation for her board services, exercisable at $0.17 per share.

Summary

• Linda Park, a director of BioLargo, Inc. (BLGO), was granted 110,294 options to purchase common stock on September 30, 2025.
• The options were issued as payment for $18,750 in fees for her services on the board of directors for the most recently completed quarterly period.
• The exercise price for these options is $0.17 per share.
• The options became exercisable immediately on September 30, 2025, and will expire on September 30, 2035.
• Following this transaction, Linda Park beneficially owns 1,164,025 shares of common stock (including these options).
• The issuance was made pursuant to the Issuer's 2024 Equity Incentive Plan.

Sentiment

Score: 6

Explanation: Slightly positive. Routine director compensation through equity aligns interests, which is generally viewed favorably. The potential for minor dilution is offset by governance and incentive alignment.

Positives

• Equity compensation aligns the director's interests with those of shareholders, fostering a shared incentive for company performance.
• The issuance is part of a pre-approved 2024 Equity Incentive Plan, indicating structured and transparent corporate governance practices.
• The exercise price of $0.17 provides a clear benchmark for future stock performance relative to the compensation, offering transparency on potential gains.

Negatives

• The issuance of new options can lead to potential future dilution for existing shareholders if and when these options are exercised.
• The compensation structure ties a portion of director fees directly to stock performance, which could be seen as a risk if the stock underperforms or experiences significant volatility.

Risks

• Dilution Risk: Exercise of these options in the future will increase the number of outstanding shares, potentially diluting the ownership percentage of existing shareholders.
• Market Price Volatility: The ultimate value realized from these options is directly tied to the future market price of BioLargo's common stock, exposing the director's compensation to market fluctuations.
• Future Performance Dependency: The financial benefit to the director from these options is contingent on the company's future performance and stock price appreciation above the exercise price.

Future Outlook

The options, exercisable from September 30, 2025, and expiring in 2035, tie a portion of director compensation to the company's long-term stock performance, aligning future incentives and potentially motivating sustained engagement.

Management Comments

• This Option was issued to Reporting Person as payment for $18,750 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan.

Industry Context

Equity-based compensation for directors is a common practice across various industries, particularly in smaller and growth-oriented companies, to conserve cash and align leadership incentives with shareholder value creation. This practice is consistent with broader trends in corporate governance emphasizing performance-linked remuneration.

Comparison to Industry Standards

• Equity compensation for directors is a standard practice, often seen in companies like BioLargo, Inc., which may prefer to conserve cash over cash payments for services.
• The specific grant size and exercise price would typically be benchmarked against peer companies of similar market capitalization and industry within the environmental technology or small-cap biotech sectors to assess competitiveness.
• The use of a formal Equity Incentive Plan (2024 Equity Incentive Plan) is a standard governance practice for managing equity awards, ensuring transparency and adherence to established policies.

Corporate Governance

Related Party Transactions

• Issuance of 110,294 stock options to Linda Park, a director, as payment for $18,750 in board services for the most recently completed quarterly period.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon option exercise; improved alignment of director's interests with shareholder value, potentially leading to better long-term performance.
• Director (Linda Park): Receives equity-based compensation, linking her financial incentives directly to the company's stock performance and providing a long-term stake in the company's success.

Next Steps

• Linda Park may choose to exercise these options at any time between September 30, 2025, and September 30, 2035, assuming the stock price is above the exercise price of $0.17.
• Continued service on the board of directors for BioLargo, Inc. is implied by the ongoing compensation for services.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a director, which is a standard practice for aligning management interests with shareholders. It does not contain information significant enough to warrant a change in investment thesis or a strong buy/sell recommendation. Investors should consider this as part of ongoing corporate governance and compensation practices rather than a material event impacting the company's fundamental valuation.

Keywords

BioLargo, BLGO, Linda Park, Director Compensation, Stock Options, Equity Incentive Plan, SEC Form 4, Insider Transaction, Corporate Governance, Beneficial Ownership